These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 36257911)
1. An evaluation of ivosidenib for the treatment of Tella SH; Mahipal A Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911 [TBL] [Abstract][Full Text] [Related]
2. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. Corrigan L; Lowery M Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133 [No Abstract] [Full Text] [Related]
3. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ? Roth GS; Neuzillet C; Sarabi M; Edeline J; Malka D; Lièvre A Eur J Cancer; 2023 Jan; 179():1-14. PubMed ID: 36463640 [TBL] [Abstract][Full Text] [Related]
7. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). Kehmann L; Berres ML; Gonzalez-Carmona M; Modest DP; Mohr R; Wree A; Venerito M; Strassburg C; Keitel V; Trautwein C; Luedde T; Roderburg C BMC Cancer; 2023 May; 23(1):470. PubMed ID: 37217885 [TBL] [Abstract][Full Text] [Related]
8. [Not Available]. Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759 [TBL] [Abstract][Full Text] [Related]
9. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Rizzo A; Ricci AD; Brandi G Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004 [TBL] [Abstract][Full Text] [Related]
10. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy]. Rabehi T; Quesada S Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495 [No Abstract] [Full Text] [Related]
11. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360 [TBL] [Abstract][Full Text] [Related]
12. Ivosidenib Boosts OS in Cholangiocarcinoma. Cancer Discov; 2021 Dec; 11(12):2953-2954. PubMed ID: 34635569 [TBL] [Abstract][Full Text] [Related]
13. Ivosidenib: an investigational drug for the treatment of biliary tract cancers. Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991 [No Abstract] [Full Text] [Related]
14. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955 [TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation. Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259 [TBL] [Abstract][Full Text] [Related]
16. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. Merters J; Lamarca A J Hepatol; 2023 Mar; 78(3):652-657. PubMed ID: 36400328 [TBL] [Abstract][Full Text] [Related]
17. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. Uson Junior PLS; Borad MJ Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492 [TBL] [Abstract][Full Text] [Related]
18. Ivosidenib: A Review in Advanced Cholangiocarcinoma. Frampton JE Target Oncol; 2023 Nov; 18(6):973-980. PubMed ID: 37855990 [TBL] [Abstract][Full Text] [Related]